BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-345@pharmaconomics
DTSTAMP:20260707T034449Z
DTSTART;VALUE=DATE:20260319
DTEND;VALUE=DATE:20260320
SUMMARY:RYTM Phase 3 — setmelanotide
DESCRIPTION:Phase 3 trial results for setmelanotide in acquired hypothalamic obesity are due Mar 19\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/ex991hopdufapressrelease.htm\n\nTrack it: https://www.pharmaconomics.com/e/345
URL:https://www.pharmaconomics.com/e/345
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:RYTM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR